Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ligstroside aglycone is a **secoiridoid polyphenol** naturally present in extra virgin olive oil and olives, chemically classified as an iridoid and a monoterpenoid derivative[2][1][8]. It is practically insoluble in water and weakly acidic. It demonstrates **antioxidant and anti-inflammatory properties**, capable of reducing oxidative stress and neutralizing free radicals[3][6][5]. Ligstroside aglycone has been shown to modulate key inflammatory and oxidative stress pathways, including downregulation of **NF-κB, MAPKs, JAK/STAT**, and **NLRP3 inflammasome** activity as well as upregulation of **Nrf2/HO-1**[3][5]. This leads to reduction in pro-inflammatory cytokines, nitric oxide production, and extracellular matrix degradation. It has potential as a **nutraceutical** for conditions characterized by inflammation and cartilage degradation such as osteoarthritis, and it is not currently approved as a pharmaceutical drug[7][9][5]. It is under investigation primarily as a natural extract or dietary supplement compound, not as a synthesized pharmaceutical entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ligstroside aglycone.